Clinical Trial Update: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living. [Phase 2]

View source ↗

Summary

A Phase 2 double-blind, placebo-controlled study with an open-label extension assessing the efficacy and safety of E2020 (donepezil) in individuals with Down sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• E2020 (donepezil) (donepezil hydrochloride)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Down Syndrome | Phase 2 | Status: COMPLETED